New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
11:25 EDTACHN, ACHN, IDIX, IDIX, BMY, BMY, MRK, MRK, RHHBY, RHHBY, GILD, GILD, VRTX, VRTXLazard's biotech analyst research team holds an analyst/industry conference call
Biotech Analyst Research Team discusses the HCV treatment outlook on an Analyst/Industry conference call. Relevant companies BMY, MRK, RHHBY, GILD, VRTX, ACHN and IDIX may be discussed on the Analyst/Industry conference call to be held on February 5 at 12 pm.
News For BMY;MRK;RHHBY;GILD;VRTX;ACHN;IDIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 23, 2015
08:01 EDTBMYBristol-Myers to acquire Flexus, potential total consideration may be $1.25B
Subscribe for More Information
07:16 EDTGILDMylan signs exclusive agreement with Gilead to distribute Solvaldi, Harvoni
Subscribe for More Information
07:04 EDTMRKMerck, NGM Biopharmaceuticals announce multi-year collaboration
NGM Biopharmaceuticals and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201, which is being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis. NGM will lead the research and development of the existing preclinical candidates and have the autonomy to identify and pursue other discovery stage programs at its discretion. Merck will have the option to license all resulting NGM programs following human proof of concept trials. If Merck exercises this option, Merck will lead global product development and commercialization for the resulting products, if approved. Under the terms of the agreement, Merck will make an upfront payment to NGM of $94M and will purchase a 15 percent equity stake in NGM for $106M at a price per share that represents a 20% premium to NGM’s most recent financing. Merck will commit up to $250M to fund all of NGM’s efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or, in certain cases, to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States. Merck will have the option to extend the research agreement for two additional two-year terms.
06:21 EDTRHHBYFacebook's shuttle drivers approve new union contract, WSJ reports
Subscribe for More Information
February 20, 2015
16:48 EDTRHHBYDow, S&P 500 finish week at record highs after Greek deal reached
Subscribe for More Information
07:23 EDTRHHBY, BMYAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTMRKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
18:25 EDTRHHBYPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
09:35 EDTGILDOption volume leaders
Option volume leaders: AAPL TSLA TWTR MCD WMT PBR SPWR WFM GILD FB SCTY according to Track Data.
09:09 EDTRHHBYLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
08:38 EDTMRKNewLink reports clinical development milestone achieved with Merck for rVSV-EBOV
NewLink Genetics (NLNK) announced that it had received notification from Merck (MRK) that the milestone event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV, Ebola, vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20M in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
06:45 EDTRHHBYStudy shows Roche's treatments equal to Eylea in most cases, NY Times says
Subscribe for More Information
05:31 EDTRHHBYExelixis announces acceptance of NDA for Genentech cobimetinib
Subscribe for More Information
05:26 EDTRHHBYFDA grants Genentech cobimetinib priority review for combination use
Subscribe for More Information
February 18, 2015
09:37 EDTGILDOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
09:04 EDTVRTXVertex data likely to show lung function improvement, says JMP Securities
Subscribe for More Information
February 17, 2015
17:13 EDTGILDPoint72 gives quarterly update on stakes
Subscribe for More Information
16:00 EDTGILDOptions Update; February 17, 2015
Subscribe for More Information
13:18 EDTGILDOmega Advisors gives quarterly update on stakes
Subscribe for More Information
09:40 EDTGILDActive equity options trading on open
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use